Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype.

Ivashchenko CY, Pipes GC, Lozinskaya IM, Lin Z, Xiaoping X, Needle S, Grygielko ET, Hu E, Toomey JR, Lepore JJ, Willette RN.

Am J Physiol Heart Circ Physiol. 2013 Sep 15;305(6):H913-22. doi: 10.1152/ajpheart.00819.2012. Epub 2013 Jul 5.

2.

Improving the developability profile of pyrrolidine progesterone receptor partial agonists.

Kallander LS, Washburn DG, Hoang TH, Frazee JS, Stoy P, Johnson L, Lu Q, Hammond M, Barton LS, Patterson JR, Azzarano LM, Nagilla R, Madauss KP, Williams SP, Stewart EL, Duraiswami C, Grygielko ET, Xu X, Laping NJ, Bray JD, Thompson SK.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):371-4. doi: 10.1016/j.bmcl.2009.10.092. Epub 2009 Oct 25.

PMID:
19926282
3.

Estrogen-induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by Selective Estrogen Receptor Modulators via estrogen receptor alpha in rat uterine cells and tissues.

Glace L, Grygielko ET, Boyle R, Wang Q, Laping NJ, Sulpizio AC, Bray JD.

Steroids. 2009 Nov-Dec;74(13-14):1015-24. doi: 10.1016/j.steroids.2009.07.011. Epub 2009 Aug 7.

PMID:
19665469
4.

2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.

Wang Y, Duraiswami C, Madauss KP, Tran TB, Williams SP, Deng SJ, Graybill TL, Hammond M, Jones DG, Grygielko ET, Bray JD, Thompson SK.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):4916-9. doi: 10.1016/j.bmcl.2009.07.100. Epub 2009 Jul 23.

PMID:
19664922
5.

Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists.

Washburn DG, Hoang TH, Frazee JS, Johnson L, Hammond M, Manns S, Madauss KP, Williams SP, Duraiswami C, Tran TB, Stewart EL, Grygielko ET, Glace LE, Trizna W, Nagilla R, Bray JD, Thompson SK.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4664-8. doi: 10.1016/j.bmcl.2009.06.081. Epub 2009 Jun 25.

PMID:
19616429
6.

Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.

Thompson SK, Washburn DG, Frazee JS, Madauss KP, Hoang TH, Lapinski L, Grygielko ET, Glace LE, Trizna W, Williams SP, Duraiswami C, Bray JD, Laping NJ.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4777-80. doi: 10.1016/j.bmcl.2009.06.055. Epub 2009 Jun 17.

PMID:
19595590
7.

Synthesis and SAR of amino acid-derived heterocyclic progesterone receptor full and partial agonists.

Hammond M, Patterson JR, Manns S, Hoang TH, Washburn DG, Trizna W, Glace L, Grygielko ET, Nagilla R, Nord M, Fries HE, Minick DJ, Laping NJ, Bray JD, Thompson SK.

Bioorg Med Chem Lett. 2009 May 15;19(10):2637-41. doi: 10.1016/j.bmcl.2009.03.146. Epub 2009 Apr 5.

PMID:
19376703
8.

Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis.

Petersen M, Thorikay M, Deckers M, van Dinther M, Grygielko ET, Gellibert F, de Gouville AC, Huet S, ten Dijke P, Laping NJ.

Kidney Int. 2008 Mar;73(6):705-15. Epub 2007 Dec 12.

9.

Inhibition of ALK5 signaling induces physeal dysplasia in rats.

Frazier K, Thomas R, Scicchitano M, Mirabile R, Boyce R, Zimmerman D, Grygielko E, Nold J, DeGouville AC, Huet S, Laping N, Gellibert F.

Toxicol Pathol. 2007 Feb;35(2):284-95.

PMID:
17366323
10.

A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.

Madauss KP, Grygielko ET, Deng SJ, Sulpizio AC, Stanley TB, Wu C, Short SA, Thompson SK, Stewart EL, Laping NJ, Williams SP, Bray JD.

Mol Endocrinol. 2007 May;21(5):1066-81. Epub 2007 Mar 13.

PMID:
17356170
11.

Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.

Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E.

J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. Epub 2006 Oct 3.

PMID:
17018693
12.

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.

Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, Patikis A, Grygielko ET, Laping NJ, Huet S.

J Med Chem. 2006 Apr 6;49(7):2210-21.

PMID:
16570917
13.

Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.

Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ.

J Pharmacol Exp Ther. 2005 Jun;313(3):943-51. Epub 2005 Mar 15.

PMID:
15769863
14.

Ganglionic tyrosine hydroxylase and norepinephrine transporter are decreased by increased sodium chloride in vivo and in vitro.

Habecker BA, Grygielko ET, Huhtala TA, Foote B, Brooks VL.

Auton Neurosci. 2003 Sep 30;107(2):85-98.

PMID:
12963419
15.

Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat.

Abrahamsen CT, Pullen MA, Schnackenberg CG, Grygielko ET, Edwards RM, Laping NJ, Brooks DP.

Pharmacology. 2002 Sep;66(1):26-30.

PMID:
12169762
16.

Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.

Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA.

Mol Pharmacol. 2002 Jul;62(1):58-64.

PMID:
12065755
17.

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.

Abrahamsen CT, Barone FC, Campbell WG Jr, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, Brooks DP.

J Pharmacol Exp Ther. 2002 Apr;301(1):21-8.

PMID:
11907153
18.

Role of caspases in human renal proximal tubular epithelial cell apoptosis.

Wong VY, Keller PM, Nuttall ME, Kikly K, DeWolf WE Jr, Lee D, Ali SM, Nadeau DP, Grygielko ET, Laping NJ, Brooks DP.

Eur J Pharmacol. 2001 Dec 21;433(2-3):135-40.

PMID:
11755144
19.

The role of transforming growth factor-beta and its receptors in human prostate smooth muscle cell fibronectin production.

Butter S, Laping NJ, Pullen M, Grygielko E, Olson B, Brooks DP.

Eur J Pharmacol. 2001 Jun 22;422(1-3):47-52.

PMID:
11430912
20.

Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan.

Wong VY, Laping NJ, Contino LC, Olson BA, Grygielko E, Brooks DP.

Physiol Genomics. 2000 Nov 9;4(1):35-42.

PMID:
11074011
21.

Osmolality: a physiological long-term regulator of lumbar sympathetic nerve activity and arterial pressure.

Scrogin KE, Grygielko ET, Brooks VL.

Am J Physiol. 1999 Jun;276(6):R1579-86. doi: 10.1152/ajpregu.1999.276.6.R1579.

PMID:
10362734

Supplemental Content

Loading ...
Support Center